Tiumbio Co Ltd. has described bromodomain-containing protein 4 (BD2 domain) (BRD4 BD2) inhibitors reported to be useful for the treatment of cancer, fibrosis, diabetes, metabolic syndrome, and renal ...

Further candidates, including inhibitors of acetyl-lysine readers (bromodomain-containing proteins), are undergoing clinical evaluation for efficacy in different cancer settings. Among the various ...

Scientists hoped that BET inhibitors designed to block the bromodomain would nip that cycle in the bud. But clinical trials have repeatedly failed to show that BET inhibitors work, particularly in ...

Detailed price information for Vyne Therapeutics Inc (VYNE-Q) from The Globe and Mail including charting and trades.

Zenith Capital Corp., a biotechnology investment company, engages in the development of bromodomain inhibitors for the treatment of cancer and other disorders with unmet medical needs. The company ...